Prospective study of bevacizumab plus temozolomide in patients with advanced neuroendocrine tumors

Journal of Clinical Oncology

Volumn 30, Issue 24, 2012, Pages 2963-2968

  Chan, Jennifer A ^a,b,e   Stuart, Keith ^c,e   Earle, Craig C ^a,b,e   Clark, Jeffrey W ^d,e   Bhargava, Pankaj ^a,b,e   Miksad, Rebecca ^c,e   Blaszkowsky, Lawrence ^d,e   Enzinger, Peter C ^a,b,e   Meyerhardt, Jeffrey A ^a,b,e   Zheng, Hui ^d   Fuchs, Charles S ^a,b,e   Kulke, Matthew H ^a,b,e  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; BEVACIZUMAB; COTRIMOXAZOLE; TEMOZOLOMIDE;

ABDOMINAL PAIN; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ANXIETY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CARCINOID; CLINICAL ARTICLE; CONSTIPATION; DEHYDRATION; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DYSPNEA; EPISTAXIS; FATIGUE; FEMALE; FEVER; HEADACHE; HERPES ZOSTER; HUMAN; HYPERTENSION; HYPONATREMIA; INTERNATIONAL NORMALIZED RATIO; LYMPHOCYTOPENIA; MALE; METASTASIS; MUCOSA INFLAMMATION; NAUSEA; PANCREATIC NEUROENDOCRINE TUMOR; PHASE 2 CLINICAL TRIAL; PNEUMOCYSTOSIS; PRIORITY JOURNAL; PROTEINURIA; PROTHROMBIN TIME; PRURITUS; RASH; SIDE EFFECT; THROMBOCYTOPENIA; VOMITING; WEIGHT REDUCTION;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DACARBAZINE; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUROENDOCRINE TUMORS; TREATMENT OUTCOME;

EID: 84865171421     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.40.3147     Document Type: Article

References (18)

1. Raymond E, Dahan L, Raoul JL, et al: Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 364:501-513, 2011
2. Yao JC, Shah MH, Ito T, et al: Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 364:514-523, 2011
3. Engstrom PF, Lavin PT, Moertel CG, et al: Streptozocin plus fluorouracil versus doxorubicin therapy for metastatic carcinoid tumor. J Clin Oncol 2:1255-1259, 1984 (Pubitemid 15202700)
4. Kouvaraki MA, Ajani JA, Hoff P, et al: Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas. J Clin Oncol 22:4762-4771, 2004
5. Moertel CG, Lefkopoulo M, Lipsitz S, et al: Streptozocin-doxorubicin, stretpozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma. N Engl J Med 326:519-523, 1992
6. Ramanathan RK, Cnaan A, Hahn RG, et al: Phase II trial of dacarbazine (DTIC) in advanced pancreatic islet cell carcinoma: Study of the Eastern Cooperative Oncology Group-E6282. Ann Oncol 12: 1139-1143, 2001 (Pubitemid 32834496)
7. Sun W, Lipsitz S, Catalano P, et al: Phase II/III study of doxorubicin with fluorouracil compared with streptozocin with fluorouracil or dacarbazine in the treatment of advanced carcinoid tumors: Eastern Cooperative Oncology Group Study E1281. J Clin Oncol 23:4897-4904, 2005 (Pubitemid 46223995)
8. Ekeblad S, Sundin A, Janson ET, et al: Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors. Clin Cancer Res 13:2986-2991, 2007 (Pubitemid 46849574)
9. Kulke MH, Stuart K, Enzinger PC, et al: Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors. J Clin Oncol 24:401-406, 2006 (Pubitemid 46630459)
10. Strosberg JR, Fine RL, Choi J, et al: First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas. Cancer 117:268-275, 2011
11. Yao JC, Phan A, Hoff PM, et al: Targeting vascular endothelial growth factor in advanced carcinoid tumor: A random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b. J Clin Oncol 26:1316-1323, 2008
12. Kulke MH, Chan JA, Meyerhardt JA, et al: A prospective phase II study of 2-methoxyestradiol administered in combination with bevacizumab in patients with metastatic carcinoid tumors. Cancer Chemother Pharmacol 68:293-300, 2011
13. Moertel CG, Hanley JA: Combination chemotherapy trials in metastatic carcinoid tumor and the malignant carcinoid syndrome. Cancer Clin Trials 2:327-334, 1979 (Pubitemid 10021790)
14. Kulke MH, Hornick JL, Frauenhoffer C, et al: O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors. Clin Cancer Res 15:338-345, 2009
15. Lai A, Tran A, Nghiemphu PL, et al: Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme. J Clin Oncol 29:142-148, 2011
16. von Moos R, Seifert B, Simcock M, et al: First-line temozolomide combined with bevacizumab in metastatic melanoma: A multicentre phase II trial (SAKK 50/07). Ann Oncol 23:531-536, 2012
17. Cannistra SA: Phase II trials in Journal of Clinical Oncology. J Clin Oncol 27:3073-3076, 2009
18. Rinke A, Müller HH, Schade-Brittinger C, et al: Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: A report from the PROMID Study Group. J Clin Oncol 27:4656-4663, 2009